T 1087/20 (RNA-directed target DNA modification/UC) vom 06.11.2024
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2024:T108720.20241106
- Datum der Entscheidung
- 6. November 2024
- Aktenzeichen
- T 1087/20
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 13793997.1
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
- Name des Antragstellers
- The Regents of the University of California
University of Vienna
Charpentier, Emmanuelle - Name des Einsprechenden
- Pohlman, Sandra M.
Griebling, Onno
TL Brand & Co Ltd
HGF Limited
Jones Day
Allergan Pharmaceuticals International Limited
Truscott, Glyn, John - Kammer
- 3.3.08
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 104(1)European Patent Convention Art 111(1)European Patent Convention Art 113(2)Rules of procedure of the Boards of Appeal 2020 Art 016(1)
- Schlagwörter
- Basis of decision - text or agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked
Apportionment of costs - (no)
Appellant may withdraw appeal any time unless abuse of procedure
Same principles apply to withdrawal consent to/approval of text of patent
Withdrawal of consent two weeks before oral proceedings, two months from communication with preliminary opinion, and in light of complexity of case - no abuse of procedure - Orientierungssatz
- -
- Zitierte Akten
- T 0073/84T 0186/84T 0490/05T 0301/12T 1663/13T 1714/14T 0040/17T 1310/19T 1484/19T 0635/21T 1995/21
- Zitierende Akten
- T 0617/20
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.
3. The requests for a different apportionment of costs are rejected.